Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Statistical challenges in the development and evaluation of marker-based clinical tests.

McShane LM.

BMC Med. 2012 May 29;10:52. doi: 10.1186/1741-7015-10-52.

2.

Assessing the value of diagnostic tests: a framework for designing and evaluating trials.

Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ.

BMJ. 2012 Feb 21;344:e686. doi: 10.1136/bmj.e686. Review. No abstract available.

PMID:
22354600
3.

Acute kidney injury biomarkers: renal angina and the need for a renal troponin I.

Goldstein SL.

BMC Med. 2011 Dec 21;9:135. doi: 10.1186/1741-7015-9-135. Review.

4.

The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria.

Abogunrin F, O'Kane HF, Ruddock MW, Stevenson M, Reid CN, O'Sullivan JM, Anderson NH, O'Rourke D, Duggan B, Lamont JV, Boyd RE, Hamilton P, Nambirajan T, Williamson KE.

Cancer. 2012 May 15;118(10):2641-50. doi: 10.1002/cncr.26544. Epub 2011 Sep 14.

5.

Biomarkers in chronic kidney disease: a review.

Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE.

Kidney Int. 2011 Oct;80(8):806-21. doi: 10.1038/ki.2011.198. Epub 2011 Jun 22. Review.

6.

Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box.

MarchiĆ² C, Dowsett M, Reis-Filho JS.

BMC Med. 2011 Apr 19;9:41. doi: 10.1186/1741-7015-9-41. Review.

7.

Global cancer statistics.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.

CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.

8.

Network biology: a direct approach to study biological function.

Emmert-Streib F, Glazko GV.

Wiley Interdiscip Rev Syst Biol Med. 2011 Jul-Aug;3(4):379-91. doi: 10.1002/wsbm.134. Epub 2010 Dec 31.

PMID:
21197659
9.

Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer.

Margel D, Pevsner-Fischer M, Baniel J, Yossepowitch O, Cohen IR.

Eur Urol. 2011 Jan;59(1):113-9. doi: 10.1016/j.eururo.2010.10.008. Epub 2010 Oct 15. Erratum in: Eur Urol. 2011 Apr;59(4):670. Pesvner-Fischer, Meirav [corrected to Pevsner-Fischer, Meirav].

PMID:
20970244
10.

Bladder cancer in 2010: how far have we come?

Jacobs BL, Lee CT, Montie JE.

CA Cancer J Clin. 2010 Jul-Aug;60(4):244-72. doi: 10.3322/caac.20077. Epub 2010 Jun 21. Review.

11.

Is it time to re-design the haematuria clinic?

Mostafid H, Persad R, Kockelbergh R, Fawcett D.

BJU Int. 2010 Mar;105(5):585-8. doi: 10.1111/j.1464-410X.2009.09108.x. Epub 2009 Dec 11. No abstract available.

12.

A unifying view of 21st century systems biology.

Vidal M.

FEBS Lett. 2009 Dec 17;583(24):3891-4. doi: 10.1016/j.febslet.2009.11.024. Review.

13.

Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.

van der Aa MN, Steyerberg EW, Bangma C, van Rhijn BW, Zwarthoff EC, van der Kwast TH.

J Urol. 2010 Jan;183(1):76-80. doi: 10.1016/j.juro.2009.08.150.

PMID:
19913254
14.

Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.

Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, Sagalowsky AI.

J Urol. 2009 Jul;182(1):52-7; discussion 58. doi: 10.1016/j.juro.2009.02.142. Epub 2009 May 17.

PMID:
19450825
15.

EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.

Mason RA, Morlock EV, Karagas MR, Kelsey KT, Marsit CJ, Schned AR, Andrew AS.

Carcinogenesis. 2009 Jul;30(7):1155-60. doi: 10.1093/carcin/bgp077. Epub 2009 Apr 16.

16.

The relationship between proteinuria and coronary risk: a systematic review and meta-analysis.

Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, Gallagher M, Turnbull F, Chalmers J, Craig J, Huxley R.

PLoS Med. 2008 Oct 21;5(10):e207. doi: 10.1371/journal.pmed.0050207. Review.

17.

Optimal management of high-risk T1G3 bladder cancer: a decision analysis.

Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM.

PLoS Med. 2007 Sep;4(9):e284.

18.
19.

Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.

Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A.

Breast Cancer Res Treat. 2008 Apr;108(3):389-97. Epub 2007 Jun 7.

PMID:
17554627
20.

Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.

Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X.

J Clin Oncol. 2005 Aug 20;23(24):5746-56.

PMID:
16110031

Supplemental Content

Support Center